TD Waterhouse Canada’s Aldeyra Therapeutics ALDX Stock Holding History

TD Waterhouse Canada’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36	Hold	15	–	–	﹤0.01%	2357
2026 Q1	$25	Hold	15	–	–	﹤0.01%	2268
2025 Q4	$78	Hold	15	–	–	﹤0.01%	1981
2025 Q3	$79	Hold	15	–	–	﹤0.01%	2005
2025 Q2	$59	Hold	15	–	–	﹤0.01%	1931
2025 Q1	$82	Hold	15	–	–	﹤0.01%	1870
2024 Q4	$75	Buy	+15	New	+$77	﹤0.01%	1896

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

TD Waterhouse Canada's ALDX Position: Q2 2026 in Review

TD Waterhouse Canada held its Aldeyra Therapeutics (ALDX) position steady in Q2 2026 at 15 shares worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #2357.

TD Waterhouse Canada first reported a position in ALDX in Q4 2024 and has held it in 7 quarters since. The position peaked at $82 in Q1 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

TD Waterhouse Canada held 15 shares of Aldeyra Therapeutics worth $36 as of Q2 2026.
TD Waterhouse Canada left its Aldeyra Therapeutics share count unchanged in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2357 holding.
TD Waterhouse Canada first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 7 quarters since.
TD Waterhouse Canada's Aldeyra Therapeutics position peaked at $82 in Q1 2025.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.